Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

Vermillion renews collaborative research agreements with John Hopkins University

Vermillion : 07 February, 2008  (New Product)
Vermillion has renewed a long-standing collaboration with Johns Hopkins University relating to the development of novel biomarkers that can be applied toward disease detection, classification and monitoring of prevalent cancers, including ovarian, breast and prostate.
Vermillion will have access to exclusive commercial rights to the discoveries made through the partnership.

'For more than seven years we have had a highly productive relationship with Dr Daniel W Chan, professor of pathology/urology/oncology/ radiology, director of the Clinical Chemistry Division in the Department of Pathology and director for the Center for Biomarker Discovery, and his team at Johns Hopkins University,' said Eric Fung, MD, PhD, chief scientific officer of Vermillion.

'Working in tandem with this distinguished institution on the discovery of clinical assays that will ultimately aid in the development of reliable diagnostic tests gives us an opportunity to address serious unmet needs in oncology.

'This dynamic collaboration has led to the development of our ovarian tumour triage test that has the potential to significantly improve patient outcomes. We look forward to expanding this steadfast relationship.'

As part of the collaboration, Vermillion will continue to provide financial support, technical assistance and access to its advanced technology platforms, while Johns Hopkins will continue to contribute cancer serum samples and the clinical and scientific expertise of its physicians and scientists.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo